Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

General Updates | Register for the 13th Miami Myeloma MRD Meeting: insights from Ola Landgren

Ola Landgren • 24 Feb 2026
General Updates
Multiple Myeloma

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center & University of Miami, Miami, FL, invites you to join the 13th Miami Myeloma MRD Meeting on April 10, 2026, with free virtual access worldwide and on-demand viewing of all sessions. This interview took place virtually.

More from Ola Landgren

Implementing bispecific antibodies in triple-class-exposed multiple myeloma
1:46
Implementing bispecific antibodies in triple-class-exposed multiple myeloma
Ola Landgren • 25 Sep 2026
Expanding our understanding of the role of the tumor microenvironment in multiple myeloma
13:35
Expanding our understanding of the role of the tumor microenvironment in multiple myeloma
Gareth Morgan et al. • 11 Apr 2026
Where the MRD community meets: collaboration and innovation at the 13th Miami Myeloma MRD Meeting
1:42
Where the MRD community meets: collaboration and innovation at the 13th Miami Myeloma MRD Meeting
Ola Landgren • 24 Feb 2026
From discovery to decision making: the evolution of MRD at the 13th Miami Myeloma MRD Meeting
2:27
From discovery to decision making: the evolution of MRD at the 13th Miami Myeloma MRD Meeting
Ola Landgren • 25 Feb 2026

Related Videos

Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myeloma
3:16
Phase II MODIFY trial: isatuximab, iberdomide, and dexamethasone in high-risk smoldering myeloma
Dean Smith • 25 Sep 2026
Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
3:29
Self-administration of bortezomib in myeloma and amyloidosis: feasibility study findings
Aditya Nair • 25 Sep 2026
MRD-guided maintenance discontinuation in myeloma: long-term results from GEM2014MAIN
2:51
MRD-guided maintenance discontinuation in myeloma: long-term results from GEM2014MAIN
David Moreno • 25 Sep 2026
Infection-related mortality in myeloma: trends, disparities and prevention strategies
1:59
Infection-related mortality in myeloma: trends, disparities and prevention strategies
Shahzad Raza • 23 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals